- ISIN
- US8902607063
- CUSIP
- 890260706
- Sector
- Healthcare
- Industry
- Biotechnology
- IPO Date
- May 10, 2012
Highlights
- Market Cap
- $160.65M
- Enterprise Value
- -$23.37M
- EPS (TTM)
- -$11.15
- Total Revenue (TTM)
- $17.56M
- Gross Profit (TTM)
- $10.28M
- EBITDA (TTM)
- -$149.18M
- Year Range
- $11.51 - $69.97
- ROA (TTM)
- -41.56%
- ROE (TTM)
- -47.19%
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
TNXP Performance Chart
Tonix Pharmaceuticals Holding Corp. (TNXP) is down 25.0% since the beginning of the year. At $12 per share, TNXP is trading 83.2% below its 52-week high of $70. Investors who bought $1,000 worth of TNXP shares 5 years ago would now be looking at an investment worth $0.
Loading charts...
Returns By Period
Tonix Pharmaceuticals Holding Corp. (TNXP) has returned -24.97% so far this year and -69.21% over the past 12 months. Over the last ten years, TNXP has returned -84.66% per year, falling short of the S&P 500 Index benchmark, which averaged 13.75% annually.
Tonix Pharmaceuticals Holding Corp.
- 1D
- -4.64%
- 1M
- -13.82%
- YTD
- -24.97%
- 6M
- -24.48%
- 1Y
- -69.21%
- 3Y*
- -87.51%
- 5Y*
- -89.19%
- 10Y*
- -84.66%
Benchmark (S&P 500 Index)
- 1D
- 0.13%
- 1M
- 5.25%
- YTD
- 11.16%
- 6M
- 11.43%
- 1Y
- 28.20%
- 3Y*
- 21.12%
- 5Y*
- 12.66%
- 10Y*
- 13.75%
TNXP Monthly Returns History
Based on dividend-adjusted daily data since May 10, 2012, TNXP's average daily return is -0.26%, while the average monthly return is -5.90%.
Historically, 32% of months were positive and 68% were negative. The best month was Jan 2023 with a return of +187.3%, while the worst month was Jun 2024 at -86.6%. The longest winning streak lasted 5 consecutive months, and the longest losing streak was 9 months.
On a daily basis, TNXP closed higher 40% of trading days. The best single day was Feb 26, 2020 with a return of +125.0%, while the worst single day was Jul 27, 2018 at -65.8%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 10.37% | -18.97% | -1.57% | -5.96% | -4.64% | -4.95% | -24.97% | ||||||
| 2025 | 29.81% | -81.64% | 127.42% | 0.76% | 120.88% | -9.55% | 4.72% | -21.36% | -18.46% | -22.93% | -14.23% | -2.19% | -52.64% |
| 2024 | -20.60% | 18.19% | -50.82% | -3.55% | -9.20% | -86.62% | -28.86% | -53.84% | -35.15% | -2.15% | 30.76% | 73.58% | -97.44% |
| 2023 | 187.33% | -37.50% | -15.56% | -12.03% | -44.92% | -11.73% | -32.28% | -9.68% | -43.61% | 8.26% | -12.20% | -22.20% | -83.46% |
| 2022 | -32.07% | -23.91% | 24.50% | -36.62% | -47.74% | -35.25% | 6.33% | -39.29% | -47.63% | -15.57% | -14.63% | 1.25% | -96.59% |
| 2021 | 44.98% | 21.60% | 7.56% | -10.94% | 3.51% | -5.93% | -35.50% | -1.41% | -14.85% | -8.17% | -15.00% | -23.76% | -47.01% |
Benchmark Metrics
Tonix Pharmaceuticals Holding Corp. has an annualized alpha of -53.31%, beta of 0.83, and R2 of 0.01 versus S&P 500 Index. Calculated based on daily prices since May 11, 2012.
- This stock participated in 265.68% of S&P 500 Index downside but only -138.80% of its upside - more exposed to losses than it benefited from rallies.
- R2 of 0.01 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- -53.31%
- Beta
- 0.83
- R²
- 0.01
- Upside Capture
- -138.80%
- Downside Capture
- 265.68%
Return for Risk
Risk / Return Rank
TNXP ranks 10 for risk / return — in the bottom 10% of stocks on our site. This means you're taking on significantly more risk than the returns justify. Consider whether the potential upside is worth the volatility, or explore alternatives with better risk / return profiles.
Return / Risk — by metrics
The table below present risk-adjusted performance metrics for Tonix Pharmaceuticals Holding Corp. (TNXP) and compare them to S&P 500 Index.
| TNXP | Benchmark | Difference | |
|---|---|---|---|
Sharpe ratioReturn per unit of total volatility | -0.78 | 2.39 | -3.17 |
Sortino ratioReturn per unit of downside risk | -1.35 | 3.25 | -4.60 |
Omega ratioGain probability vs. loss probability | 0.86 | 1.43 | -0.58 |
Calmar ratioReturn relative to maximum drawdown | -0.86 | 3.11 | -3.97 |
Martin ratioReturn relative to average drawdown | -1.09 | 14.38 | -15.47 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the Tonix Pharmaceuticals Holding Corp.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Tonix Pharmaceuticals Holding Corp. was 100.00%, occurring on Mar 3, 2025. The portfolio has not yet recovered.
The current Tonix Pharmaceuticals Holding Corp. drawdown is 100.00%.
Related event | Drawdown | Fall | Recovery | Underwater |
|---|---|---|---|---|
2025 selloff2025 | -100.00%Mar 2025 | 12y 9mo | — | 14y 21dMay 2012 - now |
Drawdown Indicators
| TNXP | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -100.00% | -56.78% | -43.22% |
Max Drawdown (1Y)Largest decline over 1 year | -80.96% | -9.10% | -71.86% |
Max Drawdown (3Y)Largest decline over 3 years | -99.88% | -18.90% | -80.98% |
Max Drawdown (5Y)Largest decline over 5 years | -100.00% | -25.43% | -74.57% |
Max Drawdown (10Y)Largest decline over 10 years | -100.00% | -33.92% | -66.08% |
Current DrawdownCurrent decline from peak | -100.00% | 0.00% | -100.00% |
Average DrawdownAverage peak-to-trough decline | -91.16% | -10.72% | -80.44% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 63.49% | 1.97% | +61.52% |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Tonix Pharmaceuticals Holding Corp. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how Tonix Pharmaceuticals Holding Corp. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for TNXP relative to other companies in the Biotechnology industry. Currently, TNXP has a P/S ratio of 6.4. This P/S ratio falls within the average range for the industry, suggesting the stock is fairly valued based on its revenue.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for TNXP in comparison with other companies in the Biotechnology industry. Currently, TNXP has a P/B value of 0.7. This P/B ratio is low compared to industry peers. It might indicate the stock is undervalued or that the company’s assets are not expected to generate strong returns.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |
Build a portfolio with TNXP
Add Tonix Pharmaceuticals Holding Corp. to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with TNXP